Moreover, a study investigated the prognostic value of IDH mutations in 99 secondary high-grade gliomas revealed that an IDH mutation did not associate with increased PFS although secondary anaplastic glioma patients with IDH mutation showed a significantly improved outcome (31). This evidence concerns the gene IDH1 and central nervous system cancer.